Judy D. Olian
At a glance: Judy D. Olian is Director at UNITED THERAPEUTICS (UTHR). Their latest SEC Form 4, filed Mar 24, 2026, reported a sale of $106K. On file: 1 purchase line ($60K) and 4 sale lines ($417K).
Disclosed holdings: about $2.4M of UTHR stock: 4,245 shares reported on their latest Form 4 (filed Mar 24, 2026), valued at the Nov 19, 2026 close of $563.33. This counts only UTHR shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
Director at Ares Management Corp (ARES); Director at UNITED THERAPEUTICS Corp (UTHR)
Purchase track record
Not enough history. Based on 1 purchase with a full 90 days of price history.
Judy D. Olian's InsiderPrint
5 trades from SEC Form 4 filings, 2026 to 2026, drawn as one fingerprint.
Reading this print: Mostly sells, trading about 5 times a year, typically $102K a trade; most sales are on a pre-planned 10b5-1 schedule.
- Bump outward: a purchase (1)
- Dent inward: a sale (4)
- One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.
Insiders with a similar print
- Alan EzekowitzDirector · FULC · 99% match
- Michael DastoorCEO · JBL · 98% match
- Jennifer JarrettCEO, President · DMRA · 97% match
- James C. Fish Jr.Director · CAT · 96% match
- William B. CyrCEO · FRPT · 95% match
Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.
Every purchase since 2026
From the SEC's insider data sets: each open-market buy by Judy D. Olian, matched to how the stock did over the next 90 days against the S&P 500.
0 of 1 buy beat the S&P 500 (0%), median -1.1% vs. the index. Small sample: treat with care. All insider buys: 46%.
| Stock | Filed | 90 days vs. S&P 500 |
|---|---|---|
| ARES | Feb 24, 2026 | -1.1% |
Buys made close together in one stock count once. Price-only returns; history, not a prediction.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Mar 24SEC | UTHRUNITED THERAPEUTICS Corp | Sell Plan | 2004,245 held (−4%) | $530.00 | $106K | +6.3% |
| Mar 16SEC | UTHRUNITED THERAPEUTICS Corp | Sell Plan | 2004,445 held (−4%) | $535.44 | $107K | +5.2% |
| Mar 9SEC | UTHRUNITED THERAPEUTICS Corp | Sell Plan | 2004,645 held (−4%) | $510.00 | $102K | +10.5% |
| Mar 2SEC | UTHRUNITED THERAPEUTICS Corp | Sell Plan | 2004,845 held (−4%) | $509.55 | $102K | +10.6% |
| Feb 24SEC | ARESAres Management CorpFirst buy | Buy | 48029,734 held (+2%) | $124.43 | $60K | -0.3% |
- Sell
Director Judy D. Olian sold $106K of UTHR at $530.00 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Judy D. Olian sold $107K of UTHR at $535.44 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Judy D. Olian sold $102K of UTHR at $510.00 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Judy D. Olian sold $102K of UTHR at $509.55 — pre-scheduled 10b5-1 plan sale.
- Buy
Director Judy D. Olian bought $60K of ARES at $124.43 — first open-market purchase in our records.
Follow Judy D. Olian
Get one email when Judy D. Olian files a new purchase or sale. Free.
At most one email a day about Judy D. Olian, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.